Document is current
Any future updates will be listed below
-
Authors
Petrovitch, Dan https://orcid.org/0000-0002-3414-9589
Victor, Sarah E. https://orcid.org/0000-0002-7944-7299
Schmidt, Adam T. https://orcid.org/0000-0001-9232-9396
Schmitz, Joy M. https://orcid.org/0000-0002-3561-4614
Meyer, Thomas D.
Stotts, Angela L. https://orcid.org/0000-0002-6042-5276
Littlefield, Andrew K. https://orcid.org/0000-0002-4725-1152
-
Funding
Funding for this research was provided by:
Texas Tech University (Distinguished Graduate Student Assistantship)
- License Information
-
More Information
Article History
Received: 14 September 2025
Accepted: 30 October 2025
First Online: 11 November 2025
Declarations
:
: TDM has received support from COMPASS Pathfinder in the form of free access to psilocybin for an open-label trial (ClinicalTrials.gov ID NCT06706232) funded by the Anne and Don Fizer Foundation, and he has been a sub-investigator for COMPASS Pathfinder during previous and/or ongoing clinical trials (including mentoring for their German sites) as part of the contract between the Sponsor and the Faillace Department of Psychiatry and Behavioral Sciences at UTHealth Houston. SEV receives an honorarium from the American Association of Suicidology for service on the Editorial Board of the journal Suicide & Life-Threatening Behavior. DP, ATS, JMS, ALS, and AKL report no actual or perceived financial or non-financial competing interests.
